Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393827 | 0.89 | KMT2A (0.42) | CYP2C9CYP2C19HPGDHTTKMT2A | |
| SCHEMBL20083856 | 0.86 | KMT2A (0.43) | CYP2C9CYP2C19HPGDHTTKMT2A | |
| SCHEMBL15203274 | 0.85 | KMT2A (0.45) | KMT2AMEN1LMNAL3MBTL1EPHX2 | |
| SCHEMBL3716250 | 0.83 | ALDH1A1 (0.46) | CYP2C9CYP2C19HPGDHTTKMT2A | |
| SCHEMBL5932125 | 0.82 | ALDH1A1 (0.44) | CYP2C9CYP2C19HPGDHTTKMT2A | |
| SCHEMBL5932136 | 0.82 | ALDH1A1 (0.45) | CYP2C9CYP2C19HPGDHTTKMT2A | |
| SCHEMBL7515731 | 0.82 | ALDH1A1 (0.44) | CYP2C9CYP2C19HPGDHTTKMT2A | |
| SCHEMBL9375305 | 0.81 | EPHX2 (0.39) | CYP2C9CYP2C19ALDH1A1CYP1A2EPHX2 | |
| SCHEMBL5933190 | 0.81 | ALDH1A1 (0.43) | CYP2C9CYP2C19HPGDHTTKMT2A | |
| SCHEMBL17209569 | 0.81 | ALOX5 (0.48) | CYP2C9CYP2C19KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256150-A1 | Enantioselective acyl transfer catalysts and their use in kinetic resolution of alcohols and desymmetrization of meso-diols | WASHINGTON UNIVERSITY | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256150-A1 | Enantioselective acyl transfer catalysts and their use in kinetic resolution of alcohols and desymmetrization of meso-diols | ADH5, DBI, ADH1A | CYP2C9 941/4885CYP2C19 1130/4885HPGD 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.